IBB

iShares Nasdaq Biotechnology ETF
NASDAQ

Real-time Quotes | Provided by Morningstar

133.47
+2.78
+2.13%
After Hours: 132.75 -0.72 -0.54% 19:48 09/25 EDT
OPEN
130.53
PREV CLOSE
130.69
HIGH
133.78
LOW
130.30
VOLUME
3.17M
TURNOVER
--
52 WEEK HIGH
146.53
52 WEEK LOW
92.15
TOTAL ASSET
9.57B
YTD YIELD
8.08%
1D
5D
1M
3M
1Y
5Y
News
Performance
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 20h ago
Queen’s Banker Is Betting Hundreds of Millions on Brexit Deal
The private bank to Queen Elizabeth II is lavishing millions of dollars in a high-stakes bet on a Brexit deal in the teeth of market scepticism.
Bloomberg · 22h ago
U.S. Stock Slide Prompts Strategists to Predict Tilt From Credit
Strategists predict a tougher period ahead for U.S. corporate bonds after a slide in equities to more appealing levels.
Bloomberg · 1d ago
'"Comprehensive health care vision" will be unveiled by @POTUS today in #NorthCarolina, according to @PressSec.' -Tweet
https://twitter.com/W7VOA/status/1309184827745337345
Benzinga · 1d ago
Immunome sets IPO terms, to raise up to $32.5 million
Immunome Inc. undefined set terms for its initial public offering, in which the Pennsylvania-based biopharmaceutical company focused on oncology looks to...
MarketWatch · 1d ago
Can’t-Lose Trades Falter With Inflation Expectations Flagging
Inflation, dormant for a decade, captured the market’s attention all summer, with unprecedented Federal Reserve stimulus and a $2 trillion federal spending package set to juice prices.
Bloomberg · 1d ago
Investors Flee Junk ETFs as High-Yield Bonds Erase Gain for Year
The exodus from high-yield debt shows few signs of easing, with investors pulling hundreds of millions of dollars more from the largest exchange-traded funds that buy junk bonds as a global index tracking the securities erases its 2020 gains.
Bloomberg · 1d ago
The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 23)
Benzinga · 1d ago
More
No Data
Learn about the latest financial forecast of IBB. Analyze the recent business situations of iShares Nasdaq Biotechnology ETF through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
Ratings
Date
Period
Agency
Ratings
08/31/2020
3 Year
Morningstar
08/31/2020
5 Year
Morningstar
08/31/2020
10 Year
Morningstar
  • Performance
  • Asset Allocation
  • Dividend History
Period
Return
Rank in Cat
1-Month
-6.1662%
--
3-Month
-1.8936%
--
6-Month
11.9477%
--
1-Year
8.0849%
--
3-Year
5.3735%
--
5-Year
3.1086%
--
10-Year
17.0547%
--
Since Inception
7.3696%
--
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
Profile
Fund Name
iShares Nasdaq Biotechnology ETF
Risk
Low risk
Inception Date
2001-02-05
Benchmark
Dow Jones US Healthcare TR
Advisor Company
iShares
Custodian
State Street Bank & Trust Co
Manager
Team Managed